Femasys Launches At-the-Market Common Stock Offering

An announcement from Femasys ( (FEMY) ) is now available.

On December 23, 2025, Femasys Inc. filed a prospectus supplement to offer and sell up to $9.8 million of its common stock under an existing Equity Distribution Agreement with Piper Sandler & Co., using an at-the-market offering program under a previously effective shelf registration. The arrangement allows Femasys, at its discretion, to direct Piper Sandler to sell shares from time to time subject to customary parameters, enhancing the company’s financial flexibility and providing an additional mechanism to raise capital as needed while operating within established securities law frameworks.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.79 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Spark’s Take on FEMY Stock

According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.

Femasys’s overall stock score is primarily influenced by its challenging financial performance, with significant issues in profitability and cash flow management. However, positive corporate events, including FDA approvals and strategic orders, provide a counterbalance, indicating potential for future growth. Technical analysis and valuation suggest cautious optimism, with mixed momentum and a negative P/E ratio.

To see Spark’s full report on FEMY stock, click here.

More about Femasys

Femasys Inc. is a publicly traded company that issues common stock with a par value of $0.001 per share and accesses the capital markets through registered equity offerings, utilizing an at-the-market equity distribution structure with Piper Sandler & Co. as its sales agent.

Average Trading Volume: 8,137,548

Technical Sentiment Signal: Sell

Current Market Cap: $50.36M

See more data about FEMY stock on TipRanks’ Stock Analysis page.